19.10.2015 Views

Yttrium-90 and Rhenium-188 Radiopharmaceuticals for Radionuclide Therapy

Pub1662web-89688003

Pub1662web-89688003

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

6.2.1.2. Determination of the number of DOTA molecules bound to rituximab<br />

The number of chelator (p-NCS-Bz-DOTA) molecules bound to rituximab<br />

was determined by two methods: radioassay using cold 89 YCl 3·6H 2 O spiked<br />

with a trace of <strong>90</strong> Y acetate <strong>and</strong> spectroscopic assay using the Cu(II) arsenazo(III)<br />

complex [6.8].<br />

(a)<br />

Radioassay<br />

Aliquots approximating to 100 µg of rituximab of each of the reaction<br />

mixtures corresponding to different antibody:DOTA molar ratios (1:10, 1:25,<br />

1:50 <strong>and</strong> 1:100) were taken. Approximately 200 µCi of <strong>90</strong> Y acetate was added,<br />

together with cold 89 YCl 3 in the ratio of 1:1 (yttrium:DOTA). The reaction<br />

was carried out at 40°C <strong>for</strong> 2 h, <strong>and</strong> the reaction mixture was purified using a<br />

PD-10 column. Fractions of 1 mL were collected using 0.05M phosphate buffer<br />

(pH7.4) <strong>and</strong> the radioactivity associated with each fraction was measured.<br />

The elution patterns are as shown in Fig. 6.5. The percentage of radioactivity<br />

associated with rituximab in comparison with the total radioactivity gave an<br />

indication of the numbers of DOTA molecules bound to the antibody, which were<br />

estimated to be ~5, 12, 20 <strong>and</strong> 36 <strong>for</strong> rituximab:DOTA conjugated at 1:10, 1:25,<br />

1:50 <strong>and</strong> 1:100 ratios, respectively.<br />

The reaction mixture of a 1:10 ratio of DOTA rituximab was spiked with<br />

cold 89 YCl 3 corresponding to 0.5:1, 1:1 <strong>and</strong> 2:1 yttrium:DOTA ratios to confirm<br />

the number of DOTA bound to rituximab. Radiolabelling was carried out as<br />

described in Section 6.2.1.4 <strong>and</strong> purification was carried out using a PD-10<br />

column. The elution patterns (see Fig. 6.6) show ~67.9%, 49% <strong>and</strong> 56.1% <strong>for</strong><br />

0.5:1, 1:1 <strong>and</strong> 2:1 yttrium:DOTA ratios, respectively. These patterns indicated<br />

that approximately five molecules of DOTA were bound to the antibody.<br />

(b)<br />

Spectroscopic assay using Cu(II) arsenazo(III) assay<br />

The number of DOTA molecules bound to rituximab was also determined<br />

using the Cu(II) arsenazo(III) assay, as reported by Brady et al. [6.8]. A stock<br />

solution referred to as copper reagent composed of 25 µM of Cu(II) <strong>and</strong> 100 µM<br />

of arsenazo(III) in 0.15M NH 4 OAc (OAc = acetate anion), pH7.0, was prepared.<br />

Serial dilutions of this reagent were made to ensure that this reagent obeyed Beer<br />

Lambert’s law by determining the absorbance at 652 nm. A spectrum of the copper<br />

reagent was taken <strong>and</strong> absorbance at 652 nm was recorded. The experiment<br />

indicated that <strong>for</strong> 1 mL of the copper arsenazo (III) reagent, absorbance (A) was<br />

0.079. Using Beer’s law, the molar extinction coefficient ε was calculated to be<br />

3160 L·cm –1 ⋅mol –1 .<br />

88

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!